

Effective Date: 9/1/2018
Reviewed Date: 8/2019, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 5/2023
Scope: Medicaid

SPECIALTY GUIDELINE MANAGEMENT

KEVZARA (sarilumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

- A. Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs)
- B. Adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

- A. Rheumatoid arthritis
 1. For initial requests:
 - a. Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.
 - b. Laboratory results, chart notes, or medical record documentation of biomarker testing (i.e., rheumatoid factor [RF], anti-cyclic citrullinated peptide [anti-CCP], and C-reactive protein [CRP] and/or erythrocyte sedimentation rate [ESR]) (if applicable).
 2. For continuation requests: Chart notes or medical record documentation supporting positive clinical response.
3. Polymyalgia rheumatica
 - a. Initial requests: Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.
 - b. Continuation requests: Chart notes or medical record documentation supporting positive clinical response.

Effective Date: 9/1/2018
Reviewed Date: 8/2019, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 5/2023
Scope: Medicaid

III. CRITERIA FOR INITIAL AND CONTINUATION OF THERAPY

For all indications:

- Prior Authorization Request is submitted by the Provider's office; AND
- Prior Authorization Request is not submitted by a pharmacy or another third party; AND
- Submission of the member's chart or medical record is required, documenting medical necessity based on the criteria corresponding to the applicable indication
- Member has had a documented negative TB test (which can include a tuberculosis skin test [PPD], an interferon-release assay [IGRA], or a chest x-ray)* within 6 months of initiating therapy for persons who are naïve to biologic DMARDs or targeted synthetic DMARDs associated with an increased risk of TB.

* If the screening testing for TB is positive, there must be further testing to confirm there is no active disease. Do not administer the requested medication to members with active TB infection. If there is latent disease, TB treatment must be started before initiation of the requested medication.

IV. CRITERIA FOR INITIAL APPROVAL

Moderately to severely active rheumatoid arthritis (RA)

A. Authorization of 12 months may be granted for treatment of moderately to severely active RA when all of the following criteria are met:

1. Prescribed by, or in consultation with, a specialist in rheumatology.
2. Member meets either of the following criteria:
 - a. Member has been tested for either of the following biomarkers and the test was positive:
 - i. Rheumatoid factor (RF)
 - ii. Anti-cyclic citrullinated peptide (anti-CCP)
 - b. Member has been tested for ALL of the following biomarkers:
 - i. RF
 - ii. Anti-CCP
 - iii. C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)
3. Member meets either of the following:
 - a. Member has experienced an inadequate response to at least a 3-month trial of methotrexate despite adequate dosing (i.e., titrated to 20 mg/week).
 - b. Member has an intolerance or contraindication to methotrexate (see Appendix).

Polymyalgia rheumatica (PMR)

Authorization of 12 months may be granted for adult members for treatment of polymyalgia rheumatica (PMR) and the Kevzara is prescribed by, or in consultation with, a specialist in rheumatology and any of the following criteria is met:

- a.
- b. Member has experienced an inadequate response to systemic corticosteroids.
- c. Member has experienced a disease flare during a taper with systemic corticosteroids.
- d. Member has experienced an inadequate response to methotrexate.

Effective Date: 9/1/2018
Reviewed Date: 8/2019, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 5/2023
Scope: Medicaid

- e. Member has experienced an intolerance or contraindication to both systemic corticosteroids and methotrexate (see Appendix).

V. CONTINUATION OF THERAPY

A. Rheumatoid Arthritis

Authorization of 12 months may be granted for all members (including new members) who are using Kevzara for an indication outlined in section II and who achieve or maintain positive clinical response as evidenced by disease activity improvement of at least 20% from baseline in tender joint count, swollen joint count, pain, or disability.

B. Polymyalgia rheumatica (PMR)

Authorization of 12 months may be granted for all adult members (including new members) who are using the requested medication for PMR and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

1. Morning stiffness
2. Hip or shoulder pain
3. Hip or shoulder range of motion
4. C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)

VI. QUANTITY LIMIT

Kevzara: 2 syringes every 4 weeks (28 days)

Indication	Dose (subcutaneous)
Rheumatoid Arthritis & Polymyalgia rheumatica	200mg once every 2 weeks

VII. APPENDIX: Examples of Contraindications to Methotrexate

1. Alcoholism, alcoholic liver disease or other chronic liver disease
2. Breastfeeding
3. Blood dyscrasias (e.g., thrombocytopenia, leukopenia, significant anemia)
4. Elevated liver transaminases
5. History of intolerance or adverse event
6. Hypersensitivity
7. Interstitial pneumonitis or clinically significant pulmonary fibrosis
8. Myelodysplasia
9. Pregnancy or planning pregnancy

Effective Date: 9/1/2018
Reviewed Date: 8/2019, 9/2020, 12/2020, 5/2021, 6/2022, 12/2022, 5/2023
Scope: Medicaid

10. Renal impairment
11. Significant drug interaction

VIII. REFERENCES

1. Kevzara [package insert]. Bridgewater, NJ: Sanofi-aventis, U.S. LLC /Regeneron Pharmaceuticals, Inc.; March 2023.
2. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. *Arthritis Rheumatol.* June 2015;67(6):1424-37.
3. Strand V, Reaney M, Chen C, et al. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. *RMD Open.* 2017; 3:e000416. doi: 10.1136/rmdopen-2016-000416.
4. Tuberculosis (TB). TB risk factors. Centers for Disease Control and Prevention. Retrieved on 21 June 2019 from: <https://www.cdc.gov/tb/topic/basics/risk.htm>.
5. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis.* 2020;79:685-699.
6. Aletaha D, Neogi T, Silman, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum.* 2010;62(9):2569-81.
7. Smolen JS, Aletaha D. Assessment of rheumatoid arthritis activity in clinical trials and clinical practice. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Available with subscription. URL: www.uptodate.com. Accessed March 19, 2021.
8. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res.* 2021;0:1-16.
9. Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. *Arthritis Rheum.* 2012 Apr;64(4):943-54.
10. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol.* 2020;82(6):1445-1486.